Technologyscience-and-technologynexsoukaiforgoodethicalaidrugdiscoverymachinelearning

Neural Acceleration in Drug Discovery: New Models Slash Computational Costs

Researchers have unveiled a significant breakthrough in computational biology with the introduction of NeRNA-Web, a unified web platform designed to generate structure-aware negative RNA sequences. According to BIOENGINEER.ORG, this tool addresses a critical bottleneck in mach...

NexSouk Generator
November 19, 2026
2 min read
0 views
0 likes
Neural Acceleration in Drug Discovery: New Models Slash Computational Costs

Researchers have unveiled a significant breakthrough in computational biology with the introduction of NeRNA-Web, a unified web platform designed to generate structure-aware negative RNA sequences. According to BIOENGINEER.ORG, this tool addresses a critical bottleneck in machine learning classification for noncoding RNA by providing a comprehensive dataset that allows scientists to compare training sets effectively. The platform's ability to create these specific negative datasets is intended to improve the accuracy of models used to identify functional RNA structures without the noise of irrelevant data.

Simultaneously, the field of drug discovery is seeing a paradigm shift with the release of STORM, a lightweight structure-free model for binding affinity prediction. As detailed in a new arXiv.org preprint, STORM was developed to overcome the prohibitive computational costs associated with traditional physics-based approaches like free-energy perturbation (FEP). While recent machine learning models such as Boltz-2 have approached the accuracy of these expensive methods, they remain too costly for large-scale screening or frequent retraining on new experimental data.

The core innovation of STORM lies in its efficiency. The model utilizes a technique called Similarity Transfer from Observed Reference Molecules, ensembling diverse protein and molecule representations to make predictions. The study indicates that STORM matches or exceeds the accuracy of Boltz-2 across multiple evaluation datasets. Crucially, it delivers a speed improvement of over five orders of magnitude for both inference and training, making high-precision affinity prediction accessible for large computational screens.

Experts suggest that this shift from heavy physics-based simulations to efficient machine learning ensembles represents a major step forward in democratizing drug discovery. By integrating historical experimental affinity data with biophysical information, the research team believes there are further opportunities to substantially improve prediction accuracy. This development could drastically reduce the time and resources required to identify potential drug candidates, potentially accelerating the path from laboratory discovery to clinical application.

The convergence of these technologies highlights a broader trend in science: the move toward making complex biological modeling faster and more accessible. While NeRNA-Web focuses on data generation for RNA classification, STORM offers a practical solution for the downstream application of binding affinity prediction. Together, they illustrate how advancements in algorithmic efficiency are reshaping the landscape of biomedical research, allowing scientists to tackle larger problems with greater speed and precision.

Follow this story

Get a notification when we publish new articles about this story.

Sources (2)

This article was written by AI from 2 news sources. Check the originals below.

Was this article helpful?

Comments & Reviews (0)

Sign in to comment and provide peer reviews

No comments yet. Be the first to share your thoughts!

Community Voice-Overs

Hear this article read aloud by community members.

Loading voiceovers…